Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover
study to evaluate the effect of deferiprone on QTc prolongation after administration of a
single therapeutic (33 mg/kg) and supratherapeutic(50 mg/kg) oral doses of deferiprone in
healthy volunteers as compared to placebo treatment.
Phase:
Phase 4
Details
Lead Sponsor:
ApoPharma
Treatments:
Deferiprone Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination